Business Offer

United States

Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) or/and peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior systemic therapy. These indications are based on response rate. Clinical benefit such as improvement in overall survival has not been demonstrated.https://www.creative-peptides.com/product/romidepsin-item-10-101-186-33671.html

[RequestAdvantages]

[RequestComments]

739

Cathy Miller